YaBeSH Engineering and Technology Library

    • Journals
    • PaperQuest
    • YSE Standards
    • YaBeSH
    • Login
    View Item 
    •   YE&T Library
    • ASME
    • Journal of Medical Devices
    • View Item
    •   YE&T Library
    • ASME
    • Journal of Medical Devices
    • View Item
    • All Fields
    • Source Title
    • Year
    • Publisher
    • Title
    • Subject
    • Author
    • DOI
    • ISBN
    Advanced Search
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Archive

    Pre-Clinical Evaluation of Direct Current Ablation for the Treatment of Benign Prostatic Hyperplasia

    Source: Journal of Medical Devices:;2009:;volume( 003 ):;issue: 002::page 27504
    Author:
    B. Fruland
    ,
    K. Anderson
    ,
    T. Larson
    ,
    M. Holtz
    ,
    S. Sundquist
    ,
    T. Nelson
    ,
    A. Kroll
    DOI: 10.1115/1.3134839
    Publisher: The American Society of Mechanical Engineers (ASME)
    Abstract: Benign Prostatic Hyperplasia (BPH) is a non-cancerous growth of the prostate gland affecting about 50% of the men over age 50. As men age, the prostate continues to grow leading to increased prostate volume, which may cause lower urinary tract symptoms (LUTS). These symptoms can include the inability to completely empty the bladder, urine retention, and a profound sensation of urgency. Direct Current (DC) ablation may be applied to treat these symptoms as a minimally-invasive alternative to surgery, medication, or thermal ablation, by causing tissue necrosis within the lateral lobes of the prostate. The objective of this study was to evaluate the effects of DC ablation in canine prostates by investigating how the resulting necrosis would change the macrostructure of the prostate for the potential treatment of symptomatic BPH. DC ablation is achieved by passing direct current through two electrodes in tissue, causing the formation of hydrogen ions at the anode and hydroxyl ions at the cathode. These ions diffuse through the tissue causing a pH of ∼1 at the anode, and ∼13 at the cathode. The extreme anti-physiological pH regions cause cellular necrosis and form in a predictable manner that is directly proportional to the charge delivered. The controlled shape and size of the lesions allow for predictable necrotic zones and enable treatment optimization. Treatment was performed on 6 acute and 8 chronic canine subject by performing a laparotomy and inserting electrodes through the prostate capsule. Acute subjects were sacrificed before recovery, while chronic subjects were sacrificed after 1, 3, 20, 40, and 60 days to investigate the healing cascade of the prostate after treatment. The chronic subjects were monitored for changes in urination or defecation patterns. Urine and blood samples were collected to evaluate the subjects' health throughout the study. Both macro-visual and pathological analyses were done to evaluate tissue response all acute and chronic subjects. Cellular necrosis within the prostate was significant and exhibited a dose response within the range of 0.07 to 0.10 cm3/coulomb for each electrode pair. The does response is defined as the ratio of necrotic tissue created, to charge delivered. Necrotic prostate cells resulted in voids with minimal scar tissue and a visible reduction in prostate mass. The treatment followed tissue planes constraining necrotic zones to the region between the prostate capsule and prostatic urethra. Both normal and hyperplastic tissues were treated and exhibited necrosis. No necrosis was observed outside the prostate. DC ablation has been demonstrated to create well-defined, predictable, and repeatable regions of cellular necrosis and structural changes in canine prostates. This technology may offer promise for the treatment of symptomatic BPH with an appropriately designed delivery system. Other potential applications include other benign and malignant tumors within the body.
    • Download: (35.33Kb)
    • Show Full MetaData Hide Full MetaData
    • Get RIS
    • Item Order
    • Go To Publisher
    • Statistics

      Pre-Clinical Evaluation of Direct Current Ablation for the Treatment of Benign Prostatic Hyperplasia

    URI
    https://yetl.yabesh.ir/yetl1/handle/yetl/141548
    Collections
    • Journal of Medical Devices

    Show full item record

    contributor authorB. Fruland
    contributor authorK. Anderson
    contributor authorT. Larson
    contributor authorM. Holtz
    contributor authorS. Sundquist
    contributor authorT. Nelson
    contributor authorA. Kroll
    date accessioned2017-05-09T00:34:41Z
    date available2017-05-09T00:34:41Z
    date copyrightJune, 2009
    date issued2009
    identifier issn1932-6181
    identifier otherJMDOA4-28002#027504_2.pdf
    identifier urihttp://yetl.yabesh.ir/yetl/handle/yetl/141548
    description abstractBenign Prostatic Hyperplasia (BPH) is a non-cancerous growth of the prostate gland affecting about 50% of the men over age 50. As men age, the prostate continues to grow leading to increased prostate volume, which may cause lower urinary tract symptoms (LUTS). These symptoms can include the inability to completely empty the bladder, urine retention, and a profound sensation of urgency. Direct Current (DC) ablation may be applied to treat these symptoms as a minimally-invasive alternative to surgery, medication, or thermal ablation, by causing tissue necrosis within the lateral lobes of the prostate. The objective of this study was to evaluate the effects of DC ablation in canine prostates by investigating how the resulting necrosis would change the macrostructure of the prostate for the potential treatment of symptomatic BPH. DC ablation is achieved by passing direct current through two electrodes in tissue, causing the formation of hydrogen ions at the anode and hydroxyl ions at the cathode. These ions diffuse through the tissue causing a pH of ∼1 at the anode, and ∼13 at the cathode. The extreme anti-physiological pH regions cause cellular necrosis and form in a predictable manner that is directly proportional to the charge delivered. The controlled shape and size of the lesions allow for predictable necrotic zones and enable treatment optimization. Treatment was performed on 6 acute and 8 chronic canine subject by performing a laparotomy and inserting electrodes through the prostate capsule. Acute subjects were sacrificed before recovery, while chronic subjects were sacrificed after 1, 3, 20, 40, and 60 days to investigate the healing cascade of the prostate after treatment. The chronic subjects were monitored for changes in urination or defecation patterns. Urine and blood samples were collected to evaluate the subjects' health throughout the study. Both macro-visual and pathological analyses were done to evaluate tissue response all acute and chronic subjects. Cellular necrosis within the prostate was significant and exhibited a dose response within the range of 0.07 to 0.10 cm3/coulomb for each electrode pair. The does response is defined as the ratio of necrotic tissue created, to charge delivered. Necrotic prostate cells resulted in voids with minimal scar tissue and a visible reduction in prostate mass. The treatment followed tissue planes constraining necrotic zones to the region between the prostate capsule and prostatic urethra. Both normal and hyperplastic tissues were treated and exhibited necrosis. No necrosis was observed outside the prostate. DC ablation has been demonstrated to create well-defined, predictable, and repeatable regions of cellular necrosis and structural changes in canine prostates. This technology may offer promise for the treatment of symptomatic BPH with an appropriately designed delivery system. Other potential applications include other benign and malignant tumors within the body.
    publisherThe American Society of Mechanical Engineers (ASME)
    titlePre-Clinical Evaluation of Direct Current Ablation for the Treatment of Benign Prostatic Hyperplasia
    typeJournal Paper
    journal volume3
    journal issue2
    journal titleJournal of Medical Devices
    identifier doi10.1115/1.3134839
    journal fristpage27504
    identifier eissn1932-619X
    treeJournal of Medical Devices:;2009:;volume( 003 ):;issue: 002
    contenttypeFulltext
    DSpace software copyright © 2002-2015  DuraSpace
    نرم افزار کتابخانه دیجیتال "دی اسپیس" فارسی شده توسط یابش برای کتابخانه های ایرانی | تماس با یابش
    yabeshDSpacePersian
     
    DSpace software copyright © 2002-2015  DuraSpace
    نرم افزار کتابخانه دیجیتال "دی اسپیس" فارسی شده توسط یابش برای کتابخانه های ایرانی | تماس با یابش
    yabeshDSpacePersian